Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.7152W HIGH $10.31
Volume
147.81 K
Value Traded
13.07 M
Short % Float
17.05%
-11.22%Week
+12.67%1 Month
+145.5%3 Month
+122.06%6 Month
-96.33%5 Year
-99.94%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
373.94 M
EPS (TTM)
2.25
P/E Ratio
3.71
Ent. Value
413.53 M
Total Shares
45.16 M
Float Shares
39.91 M
Insiders
11.64%
Institutions
38.55%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
AGEN Catalyst Timeline
Dated clinical, regulatory and corporate events for Agenus Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Agenus Inc.
839Total events
19Upcoming
208Tier-1 (high impact)
2010 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Long Term DataBotensilimabFiledClinical Data
Three-year follow-up results from ovarian cancer cohort of Phase 1b C-800-01 trial
recurrent ovarian cancersource ↗
▲Oral PresentationBotensilimabFiledPresentation
Presentation of three-year survival data at IGCS 2026
recurrent ovarian cancersource ↗
●R&D DayPresentation
Agenus to participate in H.C. Wainwright 28th Annual Global Investment Conference fireside chat
●R&D DayPresentation
Agenus to participate in Cantor Global Healthcare Conference 2026 fireside chat
▲PublicationBotensilimabFiledPresentation
Peer-reviewed publication of mature Phase 1b results in Clinical Cancer Research
microsatellite-stable metastatic colorectal cancersource ↗
▲Full ResultsBotensilimabFiledClinical Data
Mature 123 patient analysis reports 21.2-month median OS and 33% three-year OS
microsatellite-stable metastatic colorectal cancersource ↗
▲Full ResultsBotensilimabFiledClinical Data
Updated NEST Phase 2 results published in Clinical Cancer Research
resectable colon cancersource ↗
▲PublicationBotensilimabFiledPresentation
Updated NEST Phase 2 results published in Clinical Cancer Research
resectable colon cancersource ↗
▼Program DiscontinuationBotensilimabFiledCorporate
Agenus discontinued funding for BATTMAN; CCTG terminated the study
refractory MSS metastatic colorectal cancersource ↗
▼Trial DiscontinuedBotensilimabFiledTrial
BATTMAN formally terminated by CCTG
refractory MSS metastatic colorectal cancersource ↗
▼Program DiscontinuationBotensilimabFiledCorporate
Agenus discontinued funding for BATTMAN; CCTG terminated study
refractory MSS metastatic colorectal cancersource ↗
▲Oral PresentationBotensilimabFiledPresentation
بيانات بارزة لمدة ثلاث سنوات من المرحلة 1b لمجموعة C-800-01 المكتملة التسجيل
سرطان القولون والمستقيم النقيلي من النوع MSS المقاوم للعلاجsource ↗
▲Full ResultsBotensilimabFiledClinical Data
نتائج بارزة لمدة ثلاث سنوات تظهر معدل بقاء إجمالي 33%
سرطان القولون والمستقيم النقيلي من النوع MSS المقاوم للعلاجsource ↗
▲Oral PresentationBotensilimabFiledPresentation
Presentazione dei dati di riferimento a tre anni dello studio BOT+BAL a ESMO GI 2026
carcinoma colorettale metastatico MSS refrattario senza metastasi epatiche attivesource ↗
▲Oral PresentationPresentation
Presentatie van BOT+BAL resultaten op ESMO GI 2026
refractair MSS-gemetastaseerd colorectaal carcinoom zonder actieve levermetastasensource ↗
▲Oral PresentationBotensilimabFiledPresentation
Landmark BOT+BAL data showing 33% three-year overall survival presented at ESMO GI 2026
refractory MSS metastatic colorectal cancer without active liver metastasessource ↗
▲Oral PresentationBotensilimabFiledPresentation
Presentation of 3-year Phase 1b data for BOT+BAL at ESMO GI 2026
refractory MSS metastatic colorectal cancer without active liver metastasessource ↗
▲Oral PresentationBotensilimabFiledPresentation
Three-year landmark Phase 1b data for BOT+BAL presented at ESMO GI 2026
refractory microsatellite-stable metastatic colorectal cancer without active liver metastasessource ↗
▲Full ResultsBotensilimabFiledClinical Data
Three-year overall survival data: 33% at 36 months, median OS 21.2 months
refractory microsatellite-stable metastatic colorectal cancer without active liver metastasessource ↗
▲Primary Endpoint MetBotensilimabFiledClinical Data
Primary safety and tolerability endpoint met; no new safety signals
refractory microsatellite-stable metastatic colorectal cancer without active liver metastasessource ↗
▲Secondary Endpoint DataBotensilimabFiledClinical Data
Secondary endpoints: ORR 21%, DCR 69%, median DOR not reached
refractory microsatellite-stable metastatic colorectal cancer without active liver metastasessource ↗
▲Subgroup AnalysisBotensilimabFiledClinical Data
Post hoc late-line-exposed subgroup analysis
refractory microsatellite-stable metastatic colorectal cancer without active liver metastasessource ↗
▼Equity OfferingCorporate
Completed oversubscribed $85 million private placement with milestone-aligned warrants
▲Trial InitiationBotensilimabFiledTrial
First patient dosed in NEST3 Phase 2 trial
advanced resectable colorectal cancersource ↗
▲Long Term DataBotensilimabFiledClinical Data
Three-year data from Phase 1b C-800-01 cohort of botensilimab plus balstilimab show 33% overall survival rate
metastatic colorectal cancer (MSS, refractory, without active liver metastases)source ↗
◆Oral PresentationBotensilimabFiledPresentation
Three-year survival data from Phase 1b BOT+BAL study in MSS mCRC to be presented at ESMO GI 2026
MSS metastatic colorectal cancersource ↗
◆Timing GuidancePresentation
Webcast at Annual Shareholder Meeting in June 2026 to provide strategic updates
●Quarterly UpdateCorporate
Webcast in conjunction with Annual Meeting to highlight strategic priorities and data milestones
◆Oral PresentationBotensilimabFiledPresentation
First Phase 2 data for botensilimab ± balstilimab in advanced cutaneous melanoma at ASCO 2026
advanced cutaneous melanoma refractory/resistant to anti-PD-(L)1 ± CTLA-4source ↗
◆Poster PresentationBotensilimabFiledPresentation
ASCO 2026 poster presentation of AI analysis of H&E images predicting response and survival with BOT+BAL
MSS metastatic colorectal cancer, ovarian cancer, sarcomassource ↗
▲Full ResultsBotensilimabFiledClinical Data
First disclosure of Phase 2 data from C-800-23 study
advanced cutaneous melanomasource ↗
▼Equity OfferingCorporate
ATM program net proceeds of $11.7 million received after quarter-end
▲FDA Feedback ReceivedBotensilimabFiledFDA Meeting
SEC concluded investigation with no enforcement action recommended
▲Partnership / LicenseBotensilimabFiledCorporate
BAP Pharma appointed exclusive global partner for BOT+BAL access programs
●Enrollment UpdateBotensilimabFiledTrial
Approximately 1200 patients treated with botensilimab and/or balstilimab in Phase 1 and Phase 2 trials
multiple advanced cancerssource ↗
●Trial InitiationBotensilimabFiledTrial
Global Phase 3 BATTMAN trial for BOT+BAL in refractory MSS/pMMR mCRC
MSS/pMMR metastatic colorectal cancersource ↗
▲Partnership / LicenseCorporate
Agenus names BAP Pharma as exclusive global partner for BOT+BAL access programs
◆Poster PresentationBotensilimabFiledPresentation
Preliminary results of first-line botensilimab and balstilimab optimization in MSS CRC without liver, bone, or brain metastasis (BBOpCo) at AACR 2026
first-line microsatellite stable colorectal cancer (MSS CRC)source ↗
◆Oral PresentationBotensilimabFiledPresentation
Data from Phase II study of BOT+BAL+agenT-797 to be presented at AACR 2026
PD-1 refractory gastroesophageal cancersource ↗
▲First Patient DosedBotensilimabFiledTrial
BATTMAN試驗完成首例病患招募
微衛星穩定型(MSS)/錯配修復完整型(pMMR)轉移性大腸直腸癌(mCRC)source ↗
▲First Patient DosedBotensilimabFiledTrial
First patient enrolled in global Phase 3 BATTMAN trial of BOT+BAL in MSS/pMMR mCRC
MSS or pMMR metastatic colorectal cancersource ↗
▲Trial InitiationBotensilimabFiledTrial
Phase 3 BATTMAN trial commenced patient enrollment
refractory MSS/pMMR metastatic colorectal cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How AGEN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-03 | Botensilimab (BOT) + Balstilimab (BAL) | Phase 1b data presentation | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C46 / 100
Pipeline Score
$231M
Pipeline Value
Overvalued
Valuation Signal
11
Drugs Scored
0.6x
rNPV / MCap
Top 25%
Micro Cap(rank 165 of 658)
Percentile Rank
Agenus Inc. carries a moderate pipeline score (46/100), with $4.0B risk-adjusted pipeline value, led by Botensilimab in Non-small Cell Lung Cancer (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Botensilimab Monoclonal antibodyNCT05529316 | Advanced Melanoma | Phase 2 | ACTIVE NOT_RECRUITING | 150 | Feb 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every AGEN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| botensilimab and balstilimab | resectable colon cancer | Phase 2 | 2026-08-26 | significant deep pathologic responses and no recurrences observedRead More | Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| ARMEN GARO HDirector, Officer (See Remarks) | Grant/Award | 4,852 371,108 held | $3.35 | 07/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AGEN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 0.2 % (-60 %) | 5.25 M | 313.36 K | -99.01% ( -31.38 M) |
AGEN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AGEN ranks across every disease it competes in
Competitive Position is a premium feature
See how AGEN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAGEN News
AGEN▼ -1.2%today
Agenus informa una supervivencia estimada a tres años del 48 % con BOT+BAL para cáncer de ovarios recurrente en IGCS 2026
Agenus Inc. reported a three-year estimated survival rate of 48% for patients with recurrent ovarian cancer in their Phase 1b trial (C-800-01). The study evaluated the efficacy of botensilimab (BOT) combined with balstilimab (BAL), involving over 400 participants. These results highlight the potential of this combination therapy in immuno-oncology.
Read more →AGEN▼ -1.2%today
Riassunto: Agenus segnala una sopravvivenza a tre anni stimata al 48% con BOT+BAL nel tumore ovarico recidivante all'IGCS 2026
Agenus Inc. announced a three-year estimated survival rate of 48% for patients with recurrent ovarian cancer in their Phase 1b clinical trial C-800-01. The trial evaluated the combination of botensilimab (BOT) and balstilimab (BAL), involving over 400 patients. These results highlight the potential effectiveness of this immuno-oncology treatment.
Read more →AGEN▼ -1.2%today
Samenvatting: Agenus rapporteert een geschatte driejarige overleving van 48% met BOT+BAL bij recidiverende eierstokkanker tijdens IGCS 2026
Agenus Inc. has announced a three-year survival rate of 48% for patients with recurrent ovarian cancer in its Phase 1b study C-800-01. The study evaluated the efficacy of botensilimab (BOT) combined with balstilimab (BAL) and involved more than 400 patients. These results highlight the potential of this treatment combination in immuno-oncology.
Read more →AGEN▼ -1.2%today
Agenus meldet auf der IGCS 2026 eine geschätzte Dreijahresüberlebensrate von 48 % mit BOT+BAL bei rezidivierendem Eierstockkrebs
Agenus Inc. hat positive Ergebnisse aus der Dreijahres-Nachbeobachtung seiner Phase-1b-Studie C-800-01 veröffentlicht. Die Studie zeigt eine geschätzte Dreijahresüberlebensrate von 48 % bei Patientinnen mit rezidivierendem Eierstockkrebs, die mit Botensilimab und Balstilimab behandelt wurden. Diese Ergebnisse unterstreichen das Potenzial der Kombinationstherapie in der Immunonkologie.
Read more →AGEN▼ -1.2%today
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Agenus Inc. announced positive three-year follow-up results from its Phase 1b C-800-01 trial, which evaluated the combination of botensilimab and balstilimab in recurrent ovarian cancer. The trial involved over 400 patients and reported an estimated 48% survival rate. These findings highlight the potential of this immuno-oncology therapy.
Read more →AGEN▼ -1.2%today
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Agenus Inc. has announced that two posters on the long-term survival data of botensilimab (BOT) in combination with balstilimab (BAL) will be presented at the SITC 2026 Annual Meeting. The meeting is scheduled for November 4-8, 2026, in Phoenix, Arizona. This presentation underscores Agenus's commitment to advancing immuno-oncology research.
Read more →AGENAgenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Agenus Inc. announced that it will present a poster on the three-year overall survival data for botensilimab (BOT) combined with balstilimab (BAL) at the IGCS Annual Global Meeting in 2026. This study focuses on recurrent ovarian cancer and highlights the company's commitment to advancing immuno-oncology treatments. The event will occur in Montreal, Canada.
Read more →AGENAgenus to Participate in Upcoming September Investor Conferences
Agenus Inc. has announced its participation in two investor conferences scheduled for September 2026. Key executives, including Robin Taylor and Zack Armen, will engage in fireside chats and one-on-one meetings with investors. This initiative highlights the company's commitment to investor relations and transparency.
Read more →AGENAgenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Agenus Inc. has announced the publication of mature Phase 1b results for its treatment combining botensilimab (BOT) and balstilimab (BAL) in patients with microsatellite-stable metastatic colorectal cancer. The study involved 123 heavily pre-treated patients and highlighted the distinct immune-priming mechanism of the treatment. This peer-reviewed publication marks a significant advancement in immuno-oncology.
Read more →AGENAgenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Agenus Inc. has published updated results from the Phase 2 NEST trial, which evaluates neoadjuvant botensilimab and balstilimab in patients with resectable colon cancer. The findings indicate significant deep pathologic responses and no recurrences observed among participants. This publication highlights the potential of these therapies in treating localized mismatch repair-deficient colon cancer.
Read more →AGENAgenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
Agenus Inc. has reported its financial results for Q2 2026 and provided an update on its Phase 3 ROBBIN trial. The trial is evaluating the efficacy of botensilimab and balstilimab in treating high-risk, resectable microsatellite-stable colon cancer prior to surgery. The company continues to focus on its immuno-oncology innovations.
Read more →AGENAgenus to Provide Second Quarter 2026 Financial Report and Development Update
Agenus Inc. will release its second quarter 2026 financial results on August 6, 2026. The company plans to host a webcast later in August to discuss its corporate priorities. A key focus will be the acceleration of its botensilimab and balstilimab immunotherapy combination in the Phase 3 ROBBIN trial for neoadjuvant colon cancer.
Read more →AGENAgenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
Agenus Inc. has announced that three abstracts from trials on botensilimab and balstilimab have been accepted for presentation at the ESMO Congress 2026. The studies focus on neoadjuvant colorectal cancer, refractory metastatic colorectal cancer, and advanced sarcomas. This recognition highlights the company's commitment to advancing cancer treatment through immuno-oncology.
Read more →AGENAgenus meldet überzeichnete Privatplatzierung von bis zu 340 Millionen US-Dollar zur Weiterentwicklung der zulassungsrelevanten ROBBIN-Studie mit neoadjuvantem BOT+BAL bei MSS-Kolonkarzinom
Agenus Inc. has successfully completed a private placement agreement, raising approximately $85 million, with the potential to secure an additional $255 million through the exercise of warrants. This funding is intended to support the development of the pivotal ROBBIN study, focusing on neoadjuvant BOT+BAL for MSS colon cancer. The financing was led by Commodore Capital.
Read more →AGENAgenus anuncia una colocación privada sobresuscrita de hasta USD 340 millones para impulsar el ensayo registracional ROBBIN de BOT+BAL como tratamiento neoadyuvante del cáncer de colon MSS
Agenus Inc. has announced a successful oversubscribed private placement, raising approximately USD 85 million initially, with the potential for an additional USD 255 million through warrants. This funding will support the pivotal ROBBIN trial for BOT+BAL as a neoadjuvant treatment for MSS colon cancer. The financing was led by Commodore Capital.
Read more →AGENRiassunto: Agenus annuncia un collocamento privato sottoscritto in eccesso fino a 340 milioni di dollari per portare avanti il trial registrativo ROBBIN sulla combinazione neoadiuvante BOT+BAL nel tumore del colon MSS
Agenus Inc. has announced a private placement agreement expected to raise initial gross proceeds of approximately $85 million, with the potential for an additional $255 million through warrant exercises. This funding aims to support the ongoing ROBBIN trial, which focuses on the neoadjuvant combination of BOT and BAL for MSS colon cancer.
Read more →AGENSamenvatting: Agenus kondigt een overtekende onderhandse plaatsing aan van maximaal 340 miljoen dollar ter ondersteuning van de ROBBIN-registratiestudie naar neoadjuvante BOT+BAL bij MSS-darmkanker
Agenus Inc. has announced a private placement agreement aiming to raise up to $340 million to support its ROBBIN registration study for neoadjuvant BOT+BAL in MSS colorectal cancer. The initial gross proceeds are approximately $85 million, with an additional $255 million possible through the full exercise of purchase warrants. This funding is expected to bolster Agenus's capabilities in immuno-oncology.
Read more →AGEN▲ +82.7%on this newsshared move
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
Agenus Inc. has announced a successful oversubscribed private placement, raising approximately $85 million initially, with potential total proceeds of up to $340 million. The funds will be directed towards advancing the registrational ROBBIN trial for neoadjuvant BOT+BAL in MSS colon cancer. The financing was led by Commodore Capital and included several notable investors.
Read more →AGENRiassunto: Agenus condivide ad ESMO GI 2026 dati storici dello studio BOT+BAL che evidenziano una sopravvivenza globale a tre anni del 33% al carcinoma colorettale metastatico MSS refrattario senza metastasi epatiche attive
Agenus presented historical data from the BOT+BAL study at ESMO GI 2026, highlighting a three-year overall survival rate of 33% for patients with metastatic MSS colorectal cancer without active liver metastases. The findings contribute to the ongoing research in colorectal cancer treatment.
Read more →AGENSamenvatting: Agenus presenteert op ESMO GI 2026 veelbelovende resultaten van BOT+BAL: 33% totale overleving na drie jaar bij refractair MSS-gemetastaseerd colorectaal carcinoom zonder actieve levermetastasen
Agenus showcased promising results at the ESMO GI 2026 conference, highlighting a 33% overall survival rate after three years for patients with refractory MSS metastatic colorectal carcinoma without active liver metastases. This data underscores the potential of their BOT+BAL treatment in this challenging patient population.
Read more →About Agenus Inc.
Headquarters3 FORBES ROAD, LEXINGTON, MA, 02421
Founded1994
BIOPHARMAWATCH ELITE PLUS
Trade the next AGEN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime